CL2015002720A1 - Composición y kit farmacéutico de un polipéptido quimérico del factor viii y fc. - Google Patents

Composición y kit farmacéutico de un polipéptido quimérico del factor viii y fc.

Info

Publication number
CL2015002720A1
CL2015002720A1 CL2015002720A CL2015002720A CL2015002720A1 CL 2015002720 A1 CL2015002720 A1 CL 2015002720A1 CL 2015002720 A CL2015002720 A CL 2015002720A CL 2015002720 A CL2015002720 A CL 2015002720A CL 2015002720 A1 CL2015002720 A1 CL 2015002720A1
Authority
CL
Chile
Prior art keywords
composition
factor viii
chimeric polypeptide
fviii
pharmaceutical kit
Prior art date
Application number
CL2015002720A
Other languages
English (en)
Inventor
Kevin Maloney
Ahmad Abdul-Fattah
Daniel Gage
Original Assignee
Bioverativ Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50771579&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015002720(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioverativ Therapeutics Inc filed Critical Bioverativ Therapeutics Inc
Publication of CL2015002720A1 publication Critical patent/CL2015002720A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención describe una composición farmacéutica que comprende un polipéptido FVIII, particularmente una proteína de fusión que comprende FVIII recombinante sin el dominio B y una región Fc, más los excipientes: sacarosa, cloruro de sodio, L-histidina, cloruro de calcio dihidratado y polisorbato 80 o 20. También reivindica un kit que comprende un primer recipiente que comprende polvo liofilizado con FVIII y un segundo recipiente agua esterilizada con un volumen suficiente cuando se combina con el polvo liofilizado del primer recipiente una composición que comprende FVIII recombinante sin el dominio B y una región Fc, sacarosa, cloruro de sodio, L-histidina, cloruro de calcio dihidratado y polisorbato 80 o 20.
CL2015002720A 2013-03-15 2015-09-15 Composición y kit farmacéutico de un polipéptido quimérico del factor viii y fc. CL2015002720A1 (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201361800293P 2013-03-15 2013-03-15
US201361817085P 2013-04-29 2013-04-29
US201361829884P 2013-05-31 2013-05-31
US201361839477P 2013-06-26 2013-06-26
US201361863860P 2013-08-08 2013-08-08
US201361876927P 2013-09-12 2013-09-12
US201361879955P 2013-09-19 2013-09-19
US201361897742P 2013-10-30 2013-10-30

Publications (1)

Publication Number Publication Date
CL2015002720A1 true CL2015002720A1 (es) 2016-11-04

Family

ID=50771579

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002720A CL2015002720A1 (es) 2013-03-15 2015-09-15 Composición y kit farmacéutico de un polipéptido quimérico del factor viii y fc.

Country Status (21)

Country Link
US (3) US9623088B2 (es)
EP (3) EP4122487A1 (es)
JP (5) JP6330026B2 (es)
AU (3) AU2014228506A1 (es)
CA (1) CA2899737A1 (es)
CL (1) CL2015002720A1 (es)
DK (1) DK2968477T3 (es)
EA (2) EA201890671A1 (es)
ES (2) ES2776195T3 (es)
HK (1) HK1220617A1 (es)
HU (1) HUE047933T2 (es)
LT (1) LT2968477T (es)
PH (2) PH12015501801A1 (es)
PL (2) PL2968477T3 (es)
PT (2) PT2968477T (es)
RS (1) RS60003B1 (es)
SG (2) SG11201505924TA (es)
SI (1) SI2968477T1 (es)
TW (2) TWI629993B (es)
UY (1) UY35462A (es)
WO (1) WO2014144795A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201907152YA (en) * 2009-12-06 2019-09-27 Bioverativ Therapeutics Inc Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
TWI828269B (zh) 2013-03-15 2024-01-01 美商百歐維拉提夫治療公司 因子ix多肽調配物
EA201890671A1 (ru) * 2013-03-15 2019-01-31 Биовератив Терапьютикс Инк. Препараты полипептида фактора viii
CN107759694B (zh) 2016-08-19 2023-01-13 安源医药科技(上海)有限公司 双特异性抗体及其制备方法与用途
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技(上海)有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
MX2019006446A (es) 2016-12-02 2019-12-11 Bioverativ Therapeutics Inc Métodos para inducir tolerancia inmunológica a factores de coagulación.
JP7039308B2 (ja) * 2017-02-08 2022-03-22 三洋化成工業株式会社 細胞培養用担体
KR20200035130A (ko) 2017-08-09 2020-04-01 바이오버라티브 테라퓨틱스 인크. 핵산 분자 및 이의 용도
CN111655230A (zh) * 2017-11-07 2020-09-11 拉尼医疗有限公司 使用可吞服药物递送装置递送到肠道组织中的凝血因子制剂
US12030925B2 (en) 2018-05-18 2024-07-09 Bioverativ Therapeutics Inc. Methods of treating hemophilia A
BR112021002017A2 (pt) 2018-08-09 2021-05-11 Bioverativ Therapeutics Inc. moléculas de ácido nucleico e usos das mesmas para terapia genética não viral
WO2020086686A2 (en) * 2018-10-23 2020-04-30 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor viii function
JP7501875B2 (ja) * 2019-02-28 2024-06-18 公立大学法人横浜市立大学 血液凝固および/または補体異常疾患の治療用組成物
EP3956456A1 (en) 2019-04-17 2022-02-23 Codiak BioSciences, Inc. Compositions of exosomes and aav
JP2022537200A (ja) 2019-06-19 2022-08-24 バイオベラティブ セラピューティクス インコーポレイテッド 血友病および低骨ミネラル密度を処置するための方法および組成物
KR20230159284A (ko) * 2022-05-10 2023-11-21 주식회사 녹십자 혈장 단백질에 대한 신규한 액상 제형물
WO2023219379A1 (ko) * 2022-05-10 2023-11-16 주식회사 녹십자 혈장 단백질의 동결 건조를 위한 신규한 액상 제형물

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
CA1341174C (en) 1985-04-12 2001-01-30 John J. Toole Jr. Procoagulant proteins derived from factor viii: c
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
JP2525022B2 (ja) 1986-01-03 1996-08-14 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド ▲VIII▼:c因子型タンパク質の改良生産方法
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5543502A (en) 1986-06-24 1996-08-06 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
IL86693A (en) 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins that have the activity IIIV of the blood, a process for their preparation that uses cells are produced through genetic engineering and pharmaceutical preparations that contain them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
DE69029799T2 (de) 1989-02-21 1997-05-28 Washington University, St. Louis, Mo. Modifizierte formen von fortpflanzungshormonen
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
CA2106079C (en) 1991-03-15 2000-04-25 Robert C. Thompson Pegylation of polypeptides
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
ES2154650T3 (es) * 1992-10-02 2001-04-16 Genetics Inst Composicion que comprende una formulacion con factor de coagulacion viii, procedimiento para su preparacion y uso de un tensioactivo como estabilizador.
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
AU777972B2 (en) * 1999-02-22 2004-11-04 Baxalta GmbH Novel albumin-free factor VIII formulations
DK1252192T3 (da) 2000-02-11 2006-11-20 Merck Patent Gmbh Forbedring af antistofbaserede fusionsproteiners serumhalveringstid
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
DK2077121T3 (da) 2003-05-06 2011-06-06 Syntonix Pharmaceuticals Inc Koagulationsfaktor VII-Fc kimære proteiner til behandling af hæmostatiske lidelser
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
PL2298287T3 (pl) 2003-12-19 2019-02-28 Novo Nordisk Health Care Ag Stabilizowane kompozycje polipeptydów czynnika VII
HUE050542T2 (hu) 2004-11-12 2020-12-28 Bayer Healthcare Llc FVIII helyspecifikus módosítása
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US20080071063A1 (en) * 2006-02-03 2008-03-20 Medimmune, Inc. Protein Formulations
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
CA2673459C (en) * 2006-12-22 2016-09-13 Stefan Schulte Modified coagulation factors with prolonged in vivo half-life
CA2691386C (en) 2007-06-21 2014-12-23 Technische Universitaet Muenchen Biological active proteins having increased in vivo and/or in vitro stability
US8239182B2 (en) 2007-12-04 2012-08-07 Spansion Llc Data transmission system-on-chip memory model based validation
US20100286067A1 (en) 2008-01-08 2010-11-11 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
WO2010115866A1 (en) * 2009-04-06 2010-10-14 Novo Nordisk A/S Targeted delivery of factor viii proteins to platelets
SG10201907152YA (en) * 2009-12-06 2019-09-27 Bioverativ Therapeutics Inc Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
AU2012282875B2 (en) * 2011-07-08 2016-04-21 Bioverativ Therapeutics Inc. Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
CN103917554B (zh) * 2011-10-18 2017-03-08 杰特有限公司 用于改善重构后纯化的因子viii的稳定性的方法
JP2015527350A (ja) * 2012-08-13 2015-09-17 ノヴォ ノルディスク アー/エス 第viii因子の液体製剤
EP3943102A1 (en) * 2012-10-30 2022-01-26 Bioverativ Therapeutics Inc. Methods of using fviii polypeptide
EA201890671A1 (ru) * 2013-03-15 2019-01-31 Биовератив Терапьютикс Инк. Препараты полипептида фактора viii

Also Published As

Publication number Publication date
TWI629993B (zh) 2018-07-21
EA201890671A1 (ru) 2019-01-31
EA201591439A1 (ru) 2016-03-31
JP2020186268A (ja) 2020-11-19
PH12019502452A1 (en) 2021-02-08
US20210069300A1 (en) 2021-03-11
PL2968477T3 (pl) 2020-06-15
US9623088B2 (en) 2017-04-18
EP3666283A1 (en) 2020-06-17
CA2899737A1 (en) 2014-09-18
UY35462A (es) 2014-10-31
EP2968477A1 (en) 2016-01-20
EA030357B1 (ru) 2018-07-31
PH12015501801B1 (en) 2015-11-09
LT2968477T (lt) 2020-03-10
TW201842930A (zh) 2018-12-16
EP3666283B1 (en) 2022-06-08
JP2018123161A (ja) 2018-08-09
WO2014144795A1 (en) 2014-09-18
JP7240457B2 (ja) 2023-03-15
RS60003B1 (sr) 2020-04-30
JP2016516722A (ja) 2016-06-09
AU2014228506A1 (en) 2015-08-13
PT3666283T (pt) 2022-09-13
TW201501722A (zh) 2015-01-16
US20140308280A1 (en) 2014-10-16
PT2968477T (pt) 2020-03-11
HK1220617A1 (zh) 2017-05-12
EP2968477B1 (en) 2019-12-04
US10786554B2 (en) 2020-09-29
JP6330026B2 (ja) 2018-05-23
SG11201505924TA (en) 2015-09-29
AU2021277601A1 (en) 2021-12-23
SI2968477T1 (sl) 2020-04-30
US20170281734A1 (en) 2017-10-05
PL3666283T3 (pl) 2022-10-03
SG10201805207QA (en) 2018-07-30
PH12015501801A1 (en) 2015-11-09
EP4122487A1 (en) 2023-01-25
DK2968477T3 (da) 2020-03-09
HUE047933T2 (hu) 2020-05-28
ES2776195T3 (es) 2020-07-29
JP6934994B2 (ja) 2021-09-15
AU2019202656A1 (en) 2019-05-09
AU2019202656B2 (en) 2021-09-02
TWI690325B (zh) 2020-04-11
JP2021181491A (ja) 2021-11-25
JP2023060146A (ja) 2023-04-27
ES2926798T3 (es) 2022-10-28

Similar Documents

Publication Publication Date Title
CL2015002720A1 (es) Composición y kit farmacéutico de un polipéptido quimérico del factor viii y fc.
AR099079A1 (es) Variantes de región fc con propiedades de unión de fcrn modificadas
CL2015000060A1 (es) Proteína quimérica que comrpende una proteína del factor von willebrand (vwf), una secuencia xten y una proteina del factor viii; polinucleótido que la codifica; vector; célula huésped; y composición farmacéutica útil en el tratamiento de la hemofilia.
CY1124309T1 (el) Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων
CY1121953T1 (el) Κυτταροδιεισδυτικα πεπτιδια και μεθοδοι παρασκευης και χρησης αυτων
TW201613958A (en) MIC-1 fusion proteins and uses thereof
BR112017001940A2 (pt) proteínas de fusão de interleucina-2/receptor alfa de interleucina-2 e processos de uso
CY1126072T1 (el) Περιοχες gla ως θεραπευτικοι παραγοντες
CR20160049A (es) Bioconjugados de polipéptidos de apelina sintética
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
EA201790378A1 (ru) Заключенное в липосому аффинное лекарственное средство
BR112017021706A2 (pt) recipientes flexíveis com visibilidade de dispensação do produto
PE20170471A1 (es) Polipeptidos receptores formulados y metodos relacionados
CL2016000249A1 (es) Construcciones del factor de diferenciación de crecimiento 15 (gdf-15)
UY36304A (es) Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes
AR100888A1 (es) Derivados de exendina-4 como agonistas selectivos del receptor de glucagón
WO2015061416A3 (en) Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
CY1123622T1 (el) Τροποποιημενα μηνιγγιτιδοκοκκικα fhbp πολυπεπτιδια
CY1124911T1 (el) Συνθεσεις πεπτιδιων και μεθοδοι χρησης
ES2531288T3 (es) Proteína de fusión anticancerígena
BR112017007816A2 (pt) composições farmacêuticas compreendendo variantes de peptídeos e métodos de uso das mesmas
UY33983A (es) Proteínas de Unión de Tipo Anticuerpo con Región Variable Dual que Tienen Orientación de la Región de Unión con Entrecruzamiento.
BR112016025297A2 (pt) adenovírus que compreende uma porção de ligação a albumina
CO2017006898A2 (es) Formulación de relación fija de insulina glargina/lixisenatida
AR095527A1 (es) Formulaciones de polipéptido fc-factor ix